136866-33-6

Basic information

• Product Name: 1-(3,5-Dichloropyrazin-2-yl)ethanol
• Synonyms: 1-(3,5-Dichloropyrazin-2-yl)ethanol
• CAS NO: 136866-33-6
• Molecular Formula: C6H6Cl2N2O
• Molecular Weight: 193.03064
• Mol File: 136866-33-6.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 284.8±35.0 °C(Predicted)
• Appearance: /
• Density: 1.475±0.06 g/cm3(Predicted)
• PKA: 11.78±0.20(Predicted)
• CAS DataBase Reference: 1-(3,5-Dichloropyrazin-2-yl)ethanol(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(3,5-Dichloropyrazin-2-yl)ethanol(136866-33-6)
• EPA Substance Registry System: 1-(3,5-Dichloropyrazin-2-yl)ethanol(136866-33-6)

Safety Data

• Hazardous Substances Data: 136866-33-6(Hazardous Substances Data)

Usage

Chemical class

Pyrazine derivatives

Structural features

Presence of two chlorine atoms on the pyrazine ring

Structural features

An ethanol group attached to the molecule

Potential applications

Pharmaceutical industry

Potential applications

Agrochemical industry

Usage

Building block for the synthesis of various organic compounds

Safety precautions

Proper handling and compliance with regulations are necessary

Safety precautions

Ensure safety when working with the compound

Upstream product

• 4774-14-5 2,6-dichloropyrazine 
• 75-07-0 acetaldehyde 
• 75-16-1 methylmagnesium bromide 
• 136866-27-8 3,5-dichloro-pyrazine-2-carbaldehyde 

Downstream Products

• 136866-39-2 1-(3,5-dichloropyrazin-2-yl)ethan-1-one 
• 1426214-74-5 N-[4-(5-acetyl-6-chloro-pyrazin-2-yl)-phenyl]-2,3-dichloro-benzenesulfonamide 
• 1426214-73-4 2,3-dichloro-N-[4-(3-methyl-1H-pyrazolo[3,4-b]pyrazin-6-yl)phenyl]benzenesulfonamide 
• 1426214-81-4 [4-(5-acetyl-6-chloro-pyrazin-2-yl)-phenyl]-carbamic acid tert-butyl ester 
• 1426214-82-5 [4-(3-methyl-1H-pyrazolo[3,4-b]pyrazin-6-yl)-phenyl]-carbamic acid tert-butyl ester 
• 1426214-83-6 2-cyano-5-methyl-N-[4-(3-methyl-1H-pyrazolo[3,4-b]pyrazin-6-yl)phenyl]benzenesulfonamide 

Relevant articles and documents

N-[ 4 - (1H-pyrazolo [3,4-b] pyrazin-6-yl)-phenyl]-sulfamide and their use as medicaments

The invention relates to N-[4-(1H-pyrazolo[3,4-b] pyrazine-6-yl)-phenyl]-sulfonamides of a formula I. In the formula I, Ar, R1, R2 and n have meanings as shown in the claims. The compounds of the formula I are compounds which are valuable, have pharmacological activity and can adjust the activity of protein kinase, particularly the activity of serum and glucocorticoid induced kinase (SGK), and more particularly the activity of serum and glucocorticoid induced kinase isoform (SGK-1, SGK1). The compounds are suitable for treating diseases with inappropriate activity of the SGK, such as degenerative joint diseases or inflammatory process such as osteoarthritis or rheumatism. The invention also relates to a method for preparing the compounds of the formula I, an application of the compounds serving as the medicines and medicine compositions containing the compounds.

N-[ 4-(1H-pypazolo [3, 4-b] aminopyrazine-6-yl)-phenyl]-and its use as a chemical acylsulfonamide

PROBLEM TO BE SOLVED: To provide a compound effective for the treatment of diseases due to the inadequacy of serum and glucocorticoid adjustment kinase (SGK) activities, for instance, degenerative arthropathy or inflammatory process, e.g., osteoarthritis or rheumatism, to provide its use as a drug, and to provide a pharmaceutical composition containing the same. SOLUTION: The compound is represented by formula I ( wherein, Ar is selected from the group consisting of phenyl and five- or six-membered monocyclic aromatic heterocyclic rings each containing a ring heteroatom selected from the group consisting of nitrogen, oxygen and sulfur; R1 is H, amino or the like; R2 is a halogen atom, alkyl or the like; and n is 0, 1 or 2). COPYRIGHT: (C)2013,JPOandINPIT

N-[4-(1H-PYRAZOLO[3,4-B]PYRAZIN-6-YL)-PHENYL]-SULFONAMIDES AND THEIR USE AS PHARMACEUTICALS

The present invention relates to N-[4-(1H-pyrazolo[3,4-b]pyrazin-6-yl)-phenyl]-sulfonamides of the formula (I), (R2)n wherein Ar, R1, R2 and n have the meanings indicated in the claims. The compounds of the formula (I) are valuable pharmacologically active compounds which modulate protein kinase activity, specifically the activity of serum and glucocorticoid regulated kinase (SGK), in particular of serum and glucocorticoid regulated kinase isoform 1 (SGK-1, SGK1), and are suitable for the treatment of diseases in which SGK activity is inappropriate, for example degenerative joint disorders or inflammatory processes such as osteoarthritis or rheumatism. The invention furthermore relates to processes for the preparation of the compounds of the formula (I), their use as pharmaceuticals, and pharmaceutical compositions comprising them.